Metformin impairs cisplatin resistance effects in A549 lung cancer cells through mTOR signaling and other metabolic pathways
AP Morelli, TC Tortelli Jr… - International …, 2021 - spandidos-publications.com
Lung cancer is the leading cause of cancer‑associated death worldwide and exhibits
intrinsic and acquired therapeutic resistance to cisplatin (CIS). The present study …
intrinsic and acquired therapeutic resistance to cisplatin (CIS). The present study …
Metformin inhibits the proliferation of A549/CDDP cells by activating p38 mitogen-activated protein kinase
Y Wang, B Lin, J Wu, H Zhang, B Wu - Oncology letters, 2014 - spandidos-publications.com
Metformin (Met) has been widely used in hypoglycemic therapy, and it is also able to reduce
the incidence of tumors and tumor‑related mortality. The present study investigated whether …
the incidence of tumors and tumor‑related mortality. The present study investigated whether …
Metformin Induces Cytotoxicity by Down‐Regulating Thymidine Phosphorylase and Excision Repair Cross‐Complementation 1 Expression in Non‐Small Cell Lung …
JC Ko, YC Huang, HJ Chen, SC Tseng… - Basic & clinical …, 2013 - Wiley Online Library
Metformin is an antidiabetic drug recently shown to inhibit cancer cell proliferation and
growth, although the involved molecular mechanisms have not been elucidated. In many …
growth, although the involved molecular mechanisms have not been elucidated. In many …
Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription–3 activity independently of the liver kinase B1–AMP-activated …
CC Lin, HH Yeh, WL Huang, JJ Yan… - American journal of …, 2013 - atsjournals.org
Metformin has been used as first-line treatment in patients with type 2 diabetes, and is
reported to reduce cancer risk and progression by activating the liver kinase B1 (LKB1) …
reported to reduce cancer risk and progression by activating the liver kinase B1 (LKB1) …
Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1
Platinum-based chemotherapy is the standard treatment for advanced non-small-cell lung
carcinomas (NSCLCs). However, the antitumoral effect of carboplatin displays unsatisfactory …
carcinomas (NSCLCs). However, the antitumoral effect of carboplatin displays unsatisfactory …
[PDF][PDF] Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway
HY Zhou, XM Yao, XD Chen, JM Tang… - Eur Rev Med …, 2019 - europeanreview.org
OBJECTIVE: To investigate the effect of metformin (MET) on enhancing the sensitivity of
human pancreatic cancer cells to gemcitabine (GEM) by regulating the phosphatidylinositol …
human pancreatic cancer cells to gemcitabine (GEM) by regulating the phosphatidylinositol …
Combination of metformin and paclitaxel suppresses proliferation and induces apoptosis of human prostate cancer cells via oxidative stress and targeting the …
Y Zhao, X Zeng, H Tang, D Ye, J Liu - Oncology letters, 2019 - spandidos-publications.com
Previous studies have reported that metformin (MET) has anticancer activity. In combination
with chemotherapeutic drugs, MET reduces the dosage of chemotherapeutic drugs required …
with chemotherapeutic drugs, MET reduces the dosage of chemotherapeutic drugs required …
Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene
J Zhang, K Jiao, J Liu, Y Xia - Oncology letters, 2018 - spandidos-publications.com
The nuclear factor, erythroid 2 like 2 (Nrf2)/antioxidant response element (ARE) pathway has
an important role in the drug resistance of adenocarcinoma, and may act via different …
an important role in the drug resistance of adenocarcinoma, and may act via different …
Metformin enhances the sensitivity of colorectal cancer cells to cisplatin through ROS-mediated PI3K/Akt signaling pathway
P Zhang, S Zhao, X Lu, Z Shi, H Liu, B Zhu - Gene, 2020 - Elsevier
Metformin and cisplatin have been widely studied as antitumor agents. However, the effect
of metformin combined with cisplatin has not been investigated in colorectal cancer (CRC) …
of metformin combined with cisplatin has not been investigated in colorectal cancer (CRC) …
[HTML][HTML] Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism
Y Liu, C He, X Huang - Oncotarget, 2017 - ncbi.nlm.nih.gov
Platinum-based chemotherapeutic drugs are irreplaceable for the treatment of advanced
non-small cell lung cancer (NSCLC). However, acquired drug resistance has become a …
non-small cell lung cancer (NSCLC). However, acquired drug resistance has become a …